Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations

References

• World Health Organization. Prevalence and incidence of selected sexually transmitted infections. WHO Press; Geneva, Switzerland: 2011. p. 24
   Google Scholar
• Quinlivan EB, Patel SN, Grodensky CA, et al. Modeling the impact of Trichomonas vaginalis infection on HIV transmission in HIV-infected individuals in medical care. Sex Transm Dis 2012;39(9):671-7
   PubMed Web of Science ®Google Scholar
• Forna F, Gülmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev 2003;2:CD000218
   Google Scholar
• Hobbs MM, Sena AC, Swygard H, Schwebke J. Trichomonas vaginalis and trichomoniasis. In: Holmes KK, Sparling PF, Stamm WE, et al. editors, Sexually transmitted diseases, 4th Edition. McGrawHill Medical, New York, NY, USA; 2008. p. 771-94
   Google Scholar
• Langley JG, Goldsmid JM, Davies N. Venereal trichomoniasis: role of men. Genitourin Med 1987;63(4):264-7
   PubMedGoogle Scholar
• Krieger JN, Wolner-Hanssen P, Stevens C, et al. Characteristics of Trichomonas vaginalis isolates from women with and without colpitis macularis. J Infect Dis 1990;161:11.307
   PubMedGoogle Scholar
• Ryu JS, Kang JH, Jung SY, et al. Production of interleukin-8 by human neutrophils stimulated with Trichomonas vaginalis. Infect Immun 2004;72(3):326
   Google Scholar
• Conrad MD, Gorman AW, Schillinger JA, et al. Extensive genetic diversity, unique population structure and evidence of genetic exchange in the sexually transmitted parasite Trichomonas vaginalis. PLoS Negl Trop Dis 2012;6(3):e1573
   Google Scholar
• Snipes LJ, Gamard PM, Narcisi EM, et al. Molecular epidemiology of metronidazole resistance in a population of Trichomonas vaginalis clinical isolates. J Clin Microbiol 2000;38(8):3004-9
   PubMedGoogle Scholar
• Sutton M, Sternberg M, Koumans EH, et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States. 2001Clin Infect Dis 2007;45(10):1319-26
   Google Scholar
• Kissinger P, Adamski A. Trichomoniasis and HIV interactions: a review. Sex Transm Infect 2013;89(6):426-33
   PubMed Web of Science ®Google Scholar
• Balkus JE, Richardson BA, Mochache V, et al. A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women. Sex Transm Dis 2013;40(6):499-505
   PubMedGoogle Scholar
• Peterman TA, Tian LH, Metcalf CA, et al. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med 2006;145(8):564-72
   PubMedGoogle Scholar
• Niccolai LM, Kopicko JJ, Kassie A, et al. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sex Transm Dis 2000;27(5):284-8
   PubMedGoogle Scholar
• Kissinger P, Secor WE, Leichliter JS, et al. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis 2008;46(7):994-9
   PubMedGoogle Scholar
• Gaydos CA, Barnes MR, Quinn N, et al. Trichomonas vaginalis infection in men who submit self-collected penile swabs after internet recruitment. Sex Transm Infect 2013;89(6):504-8
   PubMed Web of Science ®Google Scholar
• Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens–a randomized clinical trial. Clin Infect Dis 2011;52(2):163-70
   PubMed Web of Science ®Google Scholar
• Manhart LE, Gillespie CW, Lowens MS, et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. Clin Infect Dis 2013;56(7):934-42
   PubMed Web of Science ®Google Scholar
• Lewis DA, Chirwa TF, Msimang VM, et al. Urethritis/cervicitis pathogen prevalence and associated risk factors among asymptomatic HIV-infected patients in South Africa. Sex Transm Dis 2012;39(7):531-6
   PubMedGoogle Scholar
• Wong ES, Hooton TM, Hill CC, et al. Clinical and microbiological features of persistent or recurrent nongonococcal urethritis in men. J Infect Dis 1988;158(5):1098-101
   PubMedGoogle Scholar
• Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother 2006;50(12):4209-10
   PubMed Web of Science ®Google Scholar
• Nye MB, Schwebke JR, Body BA. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol 2009;200(2):188.e1-7
   Google Scholar
• Kaydos SC, Swygard H, Wise SL, et al. Development and validation of a urine-based PCR-ELISA for use in clinical research settings to detect Trichomonas vaginalis in women. J Clin Microbiol 2003;41(1):318-23
   PubMedGoogle Scholar
• Hobbs MM, Lapple DM, Lawing LF, et al. Methods for detection of Trichomonas vaginalis in the male partners of infected women: implications for control of trichomoniasis. J Clin Microbiol 2006;44(11):3994-9
   PubMed Web of Science ®Google Scholar
• Schwebke JR, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial. J Clin Microbiol 2011;49(12):4106-11
   PubMedGoogle Scholar
• Van Der Pol B, Williams JA, Orr DP, et al. Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis 2005;192(12):2039-44
   PubMed Web of Science ®Google Scholar
• Bianchi A, Bogard M, Cessot G, et al. Kinetics of Chlamydia trachomatis clearance in patients with azithromycin, as assessed by first void urine testing by PCR and transcription-mediated amplification. Sex Transm Dis 1998;25(7):366-7
   PubMedGoogle Scholar
• Bachmann LH, Desmond RA, Stephens J, et al. Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhea. J Clin Microbiol 2002;40(10):3596-601
   PubMedGoogle Scholar
• Dunne RL, Dunn LA, Upcroft P, et al. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res 2003;13(4):239-49
   PubMed Web of Science ®Google Scholar
• Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999;36(5):353-73
   PubMed Web of Science ®Google Scholar
• Nix DE, Tyrrell R, Müller M. Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis. Antimicrob Agents Chemother 1995;39(8):1848-52
   PubMedGoogle Scholar
• Larsen B, Wilson AH, Glover DD, Charles D. Implications of metronidazole pharmacodynamics for therapy of trichomoniasis. Gynecol Obstet Invest 1986;21(1):12-18
   PubMedGoogle Scholar
• Roy RB, Laird SM, Heasman L. Treatment of trichomoniasis in the female. A comparison of metronidazole and nimorazole. Br J Vener Dis 1975;51(4):281-4
   PubMedGoogle Scholar
• Thin RN, Symonds MAE, Booker R, et al. Double-blind comparison of a single dose and a five-day course of metronidazole in the treatment of trichomoniasis. Br J Vener Dis 1979;55(5):354-6
   PubMedGoogle Scholar
• Hager WD, Brown ST, Kraus SJ, et al. Metronidazole for vaginal trichomoniasis. JAMA 1980;244(11):1219-20
   PubMed Web of Science ®Google Scholar
• Aubert JM, Sesta HJ. Treatment of vaginal trichomoniasis. Single, 2-gram dose of metronidazole as compared with a seven-day course. J Reprod Med 1982;27(12):743-5
   PubMedGoogle Scholar
• Tidwell BH, Lushbaugh WB, Laughlin MD, et al. A double-blind placebo- controlled trial of single-dose intravaginal versus single-dose oral metronidazole in the treatment of trichomonal vaginitis. J Infect Dis 1994;170(1):242-6
   PubMedGoogle Scholar
• Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr 2010;55(5):565-71
   PubMedGoogle Scholar
• CDC. Sexually Transmitted Diseases Treatment Guidelines. 2010. MMWR 2010;59(RR-12):58-61
   Google Scholar
• duBouchet L, McGregor JA, Ismail M, McCormack WM. A pilot study of metronidazole vaginal gel versus oral metronidazole for the treatment of Trichomonas vaginalis vaginitis. Sex Transm Dis 1998;25(3):176-9
   PubMed Web of Science ®Google Scholar
• Schwebke JR, Lensing SY, Sobel J. Intravaginal metronidazole/miconazole for the treatment of vaginal trichomoniasis. Sex Transm Dis 2013;40(9):710-14
   PubMedGoogle Scholar
• Skerk V, Schönwald S, Granić J, et al. Chronic prostatitis caused by Trichomonas vaginalis–diagnosis and treatment. J Chemother 2002;14(5):537-8
   PubMed Web of Science ®Google Scholar
• Hillström L, Pettersson L, Pálsson E, Sandström SO. Comparison of ornidazole and tinidazole in single-dose treatment of trichomoniasis in women. Br J Vener Dis 1977;53(3):193-4
   PubMedGoogle Scholar
• Anjaeyulu R, Gupte SA, Desai DB. Single-dose treatment of trichomonal vaginitis: a comparison of tinidazole and metronidazole. J Int Med Res 1977;5(6):438-41
   PubMedGoogle Scholar
• Manorama HT, Shenoy DR. Single-dose oral treatment of vaginal trichomoniasis with tinidazole and metronidazole. J Int Med Res 1978;6(1):46-9
   PubMedGoogle Scholar
• Crowell AL, Sanders-Lewis KA, Secor WE. In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob Agents Chemother 2003;47:1407-9
   PubMed Web of Science ®Google Scholar
• Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001;33(8):1341-6
   PubMedGoogle Scholar
• Hamed KA, Studemeister AE. Successful response of metronidazole-resistant trichomonal vaginitis to tinidazole. A case report. Sex Transm Dis 1992;19(6):339-40
   PubMedGoogle Scholar
• Bosserman EA, Helms DJ, Mosure DJ, et al. Utility of antimicrobial susceptibility testing in Trichomonas vaginalis-infected women with clinical treatment failure. Sex Transm Dis 2011;38(10):983-7
   PubMedGoogle Scholar
• Helms DJ, Mosure DJ, Secor WE, Workowski KA. Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 2008;198(4):370.e1-7
   Google Scholar
• Meingassner JG, Thurner J. Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles. Antimicrob Agents Chemother 1979;15(2):254-7
   PubMedGoogle Scholar
• Lossick JG, Müller M, Gorrell TE. In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractory vaginal trichomoniasis. J Infect Dis 1986;153(5):948-55
   PubMed Web of Science ®Google Scholar
• Schmid G, Narcisi E, Mosure D, et al. Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med 2001;46(6):545-9
   PubMedGoogle Scholar
• Rasoloson D, Tomkova E, Cammack R, et al. Metronidazole-resistant strains of Trichomonas vaginalis display increased susceptibility to oxygen. Parasitology 2001;123(Pt 1):45-6
   PubMedGoogle Scholar
• Rasoloson D, Vanacova S, Tomkova E, et al. Mechanisms of in vitro development of resistance to metronidazole in Trichomonas vaginalis. Microbiology 2002;148(Pt 8):2467-77
   PubMedGoogle Scholar
• Kirkcaldy RD, Augostini P, Asbel LE, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010. Emerg Infect Dis 2012;18(6):939-43
   PubMed Web of Science ®Google Scholar
• Saurina G, DeMeo L, McCormack WM. Cure of metronidazole- and tinidazole-resistant trichomoniasis with use of high-dose oral and intravaginal tinidazole. Clin Infect Dis 1998;26(5):1238-9
   PubMedGoogle Scholar
• Goodhew EB, Secor WE. Drug library screening against metronidazole-sensitive and metronidazole-resistant Trichomonas vaginalis isolates. Sex Transm Infect 2013;89(6):479-84
   PubMed Web of Science ®Google Scholar
• Blaha C, Duchêne M, Aspöck H, Walochnik J. In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis. J Antimicrob Chemother 2006;57(2):273-8
   PubMedGoogle Scholar
• Pérez-Villanueva J, Romo-Mancillas A, Hernández-Campos A, et al. Antiprotozoal activity of proton-pump inhibitors. Bioorg Med Chem Lett 2011;21(24):7351-4
   PubMed Web of Science ®Google Scholar
• Dunn LA, Andrews KT, McCarthy JS. The activity of protease inhibitors against Giardia duodenalis and metronidazole-resistant Trichomonas vaginalis. Int J Antimicrob Agents 2007;29(1):98-102
   PubMed Web of Science ®Google Scholar
• Ibrahim AN. Comparison of in vitro activity of metronidazole and garlic-based product (Tomex®) on Trichomonas vaginalis. Parasitol Res 2013;112(5):2063-7
   PubMedGoogle Scholar
• El-Sherbiny GM, El Sherbiny ET. The effect of Commiphora molmol (myrrh) in treatment of Trichomoniasis vaginalis infection. Iran Red Crescent Med J 2011;13(7):480-6
   PubMedGoogle Scholar
• Cargnin ST, Vieira Pde B, Cibulski S, et al. Anti-Trichomonas vaginalis activity of Hypericum polyanthemum extract obtained by supercritical fluid extraction and isolated compounds. Parasitol Int 2013;62(2):112-17
   PubMedGoogle Scholar
• Ofer K, Gold D, Flescher E. Methyl jasmonate induces cell cycle block and cell death in the amitochondriate parasite Trichomonas vaginalis. Int J Parasitol 2008;38(8-9):959-68
   PubMedGoogle Scholar
• Frasson AP, dos Santos O, Duarte M, et al. First report of anti-Trichomonas vaginalis activity of the medicinal plant Polygala decumbens from the Brazilian semi-arid region, Caatinga. Parasitol Res 2012;110(6):2581-7
   PubMedGoogle Scholar
• El-Sherbini GM, Ibrahim KM, El Sherbiny ET, et al. Efficacy of Punica granatum extract on in-vitro and in-vivo control of Trichomonas vaginalis. J Egypt Soc Parasitol 2010;40(1):229-44
   PubMedGoogle Scholar
• Mallo N, Lamas J, Leiro JM. Hydrogenosome metabolism is the key target for antiparasitic activity of resveratrol against Trichomonas vaginalis. Antimicrob Agents Chemother 2013;57(6):2476-84
   PubMedGoogle Scholar
• Tiwari P, Singh D, Singh MM. Anti-Trichomonas activity of Sapindus saponins, a candidate for development as microbicidal contraceptive. J Antimicrob Chemother 2008;62(3):526-34
   PubMedGoogle Scholar
• Scopel M, dos Santos O, Frasson AP, et al. Anti-Trichomonas vaginalis activity of marine associated fungi from the South Brazilian Coast. Exp Parasitol 2013;133(2):211-16
   PubMedGoogle Scholar
• Chen MY, Smith NA, Fox EF, et al. Acetarsol pessaries in the treatment of metronidazole resistant Trichomonas vaginalis. Int J STD AIDS 1999;10(4):277-80
   PubMedGoogle Scholar
• Muzny C, Barnes A, Mena L. Symptomatic Trichomonas vaginalis infection in the setting of severe nitroimidazole allergy: successful treatment with boric acid. Sex Health 2012;9(4):389-91
   PubMedGoogle Scholar
• Goldman LM, Upcroft JA, Workowski K, Rapkin A. Treatment of metronidazole-resistant Trichomonas vaginalis. Sex Health 2009;6(4):345-7
   PubMedGoogle Scholar
• Aggarwal A, Shier RM. Recalcitrant Trichomonas vaginalis infections successfully treated with vaginal acidification. J Obstet Gynaecol Can 2008;30(1):55-8
   PubMedGoogle Scholar
• Tayal SC, Ochogwu SA, Bunce H. Paromomycin treatment of recalcitrant Trichomonas vaginalis. Int J STD AIDS 2010;21(3):217-18
   PubMed Web of Science ®Google Scholar
• Nyirjesy P, Sobel JD, Weitz MV, et al. Difficult-to-treat trichomoniasis: results with paromomycin cream. Clin Infect Dis 1998;26(4):986-8
   PubMed Web of Science ®Google Scholar
• Nyirjesy P, Gilbert J, Mulcahy LJ. Resistant trichomoniasis: successful treatment with combination therapy. Sex Transm Dis 2011;38(10):962-3
   PubMedGoogle Scholar
• Dan M, Sobel JD. Failure of nitazoxanide to cure trichomoniasis in three women. Sex Transm Dis 2007;34(10):813-14
   PubMedGoogle Scholar
• Mammen-Tobin A, Wilson JD. Management of metronidazole-resistant Trichomonas vaginalis–a new approach. Int J STD AIDS 2005;16(7):488-90
   PubMedGoogle Scholar
• Henderson JN, Tait IB. The use of povidone-iodine (‘Betadine’) pessaries in the treatment of candidal and trichomonal vaginitis. Curr Med Res Opin 1975;3(3):157-62
   PubMedGoogle Scholar
• Antonelli NM, Diehl SJ, Wright JW. A randomized trial of intravaginal nonoxynol 9 versus oral metronidazole in the treatment of vaginal trichomoniasis. Am J Obstet Gynecol 2000;182(5):1008-10
   PubMedGoogle Scholar
• Wong CA, Wilson PD, Chew TA. Povidone-iodine in the treatment of metronidazole-resistant Trichomonas vaginalis. Aust N Z J Obstet Gynaecol 1990;30(2):169-71
   PubMedGoogle Scholar
• Livengood CH 3rd, Lossick JG. Resolution of resistant vaginal trichomoniasis associated with the use of intravaginal nonoxynol-9. Obstet Gynecol 1991;78(5 Pt 2):954-6
   PubMedGoogle Scholar
• Sharma RS, Mathur AK, Chandhiok N, et al. Phase II clinical trial with Praneem polyherbal tablets for assessment of their efficacy in symptomatic women with abnormal vaginal discharge (an ICMR task force study). Trans R Soc Trop Med Hyg 2009;103(2):167-72
   PubMedGoogle Scholar
• Moraes ME, Cunha GH, Bezerra MM, et al. Efficacy of the Mentha crispa in the treatment of women with Trichomonas vaginalis infection. Arch Gynecol Obstet 2012;286(1):125-30
   PubMed Web of Science ®Google Scholar
• Hoots BE, Peterman TA, Torrone EA, et al. A Trich-y question: should Trichomonas vaginalis infection be reportable? Sex Transm Dis 2013;40(2):113-16
   PubMed Web of Science ®Google Scholar